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Abstract Multi-gene cancer panels often identify variants of
uncertain clinical significance (VUS) that pose a challenge to
health care providers in managing a patient’s cancer risk.
Family segregation analysis can yield powerful data to re-
classify a VUS (as either benign or pathogenic). However,
financial and personnel resources to coordinate these studies
are limited. In an informal assessment we found that family
studies for variant classification are done by most clinical
genetics laboratories that offer hereditary cancer panel testing.
The process for family studies differs substantially across lab-
oratories. One near universal limitation is that families usually
have too few individuals for an informative co-segregation
analysis. A unique and potential resource-saving approach is
to engage patients and their families in expanding their own
pedigrees for segregation analysis of their VUS.We describe a
novel public educational tool (FindMyVariant.org) designed
to inform patients and genetic counselors about strategies to
improve the probability of variant classification using familial
segregation. While the web tool is designed to be useful for
any gene, the project was primarily focused on VUS’s
returned in cancer risk genes. FindMyVariant.org is a
resource for genetic providers to offer motivated families
who are willing to gather information about their family
relationships and history. Working alongside clinical or
research genetic laboratories, the information they collect
may help reclassify their VUS using segregation analysis.
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Introduction
Panel gene sequencing has become an increasingly important
strategy for evaluating inherited disease risk. Gene panels are
now available for the work-up of conditions such as
aortopathy, arrhythmia, cancer syndromes, cardiomyopathy,
epilepsy, immunodeficiency, mitochondrial disorders, and X-
linked intellectual disability (Chambers et al. 2016; Falk et al.
2012; Green et al. 2015; Hunter et al. 2014; Pritchard et al.
2014; Walsh et al. 2011). Expanded gene panels are more
sensitive than single gene testing, and are often more cost
effective than sequential testing, leading to additional diagnos-
tic and prevention opportunities (Gallego et al. 2015).
However, these panels have the caveat of also identifying rare
variants of uncertain clinical significance (VUS) in a higher
proportion of patients compared to single gene testing alone
(Cragun et al. 2014; Kurian et al. 2014; Maron et al. 2012;
Maxwell et al. 2014; Tung et al. 2014). AVUS typically has
some characteristics or associated data indicating the variant
may be deleterious, but not enough information to definitively
classify it as disease causing, or pathogenic. Millions of such
variants are present at low frequencies in the population (Lek
et al. 2015).
The finding of a VUS can be problematic for patients and
clinicians working in a clinical genetics setting (Culver et al.
2013; O’Neill et al. 2006; van Dijk et al. 2006; Vos et al.
2008). Although definitive re-classification of a VUS as path-
ogenic or benign may eventually occur, the timeline is typi-
cally many years, and may be indefinite for rare VUS,
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especially if the disease is uncommon (Lindor et al. 2013;
Murray et al. 2011; O’Neill et al. 2009). In-silico or functional
research studies usually cannot resolve the clinical signifi-
cance of a variant (Katsonis et al. 2014; Lindor et al. 2012;
Moghadasi et al. 2013; Schulz et al. 2015). While family seg-
regation studies have the potential to yield powerful data to
classify variants, many challenges emerge that limit this po-
tential. The resources needed to identify distant family mem-
bers and build the large pedigrees necessary to have enough
information for informative segregation analysis are inade-
quate. (Goldgar et al. 2008; Mohammadi et al. 2009). While
research studies dedicated to investigating rare variants in
families could impact individual families, current research re-
sources and funding are limited and unlikely to have an influ-
ential impact on a large number of families.
Most clinical genetics laboratories that offer multigene can-
cer panel testing do family studies for variant classification;
however, practices and policies vary. Recognizing the need to
assess the current landscape of family studies across clinical
labs, we performed an informal assessment of 12 clinical lab-
oratories located in the United States that offer cancer
multigene panel testing using Next Generation Sequencing
to determine their current VUS classification activities and
procedures.
A major limitation to family studies for VUS reclassifica-
tion is that the size of the family reported to genetics providers
in clinical visits often includes only three generations of rela-
tives and is too small to enable VUS classification (Eggington
et al. 2013; Shirts et al. 2013). A majority of patients will have
sufficient relatives to reclassify VUS within their first and
second cousins (B.H. Shirts and Rosenthal 2015). However,
explanation of the details of familial co-segregation studies
may be beyond the scope of what could be expected of a
genetics provider in routine clinical care.
In response to needs of patients with VUS reports and
genetics providers who may be interested in family studies
to classify VUS, we developed a novel public educational tool
designed to inform patients and genetic counselors about strat-
egies to improve the probability of VUS re-classification
using familial segregation. The website will also be a resource
for patients, genetic counselors, and other health professionals
seeking clinical laboratories and research studies that perform
family analysis for VUS classification. This web resource can
be found at FindMyVariant.org.
Assessment of Genetics Laboratories Offering
Family Analysis Services for VUS Classification
We contacted 12 commercial clinical genetics laboratories by
telephone and email and asked about current VUS re-
classification activities, policies, and procedures between
July and November 2015. Our questions were designed to
include any VUS re-classification services as follow up on
VUS findings in any tested gene where a VUS has been iden-
tified. Although these services benefit families that are able to
reclassify their VUS, as accurate classification enables appro-
priate clinical care, (Murray et al. 2011), there is no
established standard of care for VUS re-classification using
family studies. Our goal was not to formally compare labora-
tories across specific metrics, but rather, to learn the current
landscape of VUS re-classification practices.
We initially asked laboratories several broad questions: Is
there a family studies program in place? What are the criteria
and/or policy for eligibility? And what is the process for en-
rollment and sample collection? Based on responses we asked
for clarification. We re-contacted several laboratories for clar-
ification and to gather additional information. Representatives
of each laboratory were given the opportunity to review final
content for accuracy, although not all laboratories responded
to our queries. Information about Myriad Genetics was gath-
ered from the BMyVision^ Variant Classification Program
website. In addition to the laboratories listed in Table 1, we
contacted Quest and Prevention Genetics, but these laborato-
ries had no description of family studies on their respective
web sites and did not respond to our phone queries. Because
of the lack of community standards for VUS classification
activities and the wide variety of practices, our assessment
was not designed as a formal survey.
Assessment Results
There are similarities and differences across the labs (See
Table 1). Several commercial genetics laboratories (e.g.,
Ambry, GeneDx, Invitae) have family studies programs in
place with well-developed inclusion/exclusion criteria and/or
policies. For example, one lab excludes certain genes from
their family studies program, such as low-moderate pene-
trance cancer genes like ATM, BARD1, BRIP1, CHEK2,
MRE11A, NBN, RAD50, RAD51C, and RAD51D. Other lab-
oratories tend to review family studies candidates on a case-
by-case basis (e.g., ARUP laboratories, GeneDx, the
University of Washington). Nearly all laboratories offer no
laboratory fee for familial single-site testing for relatives that
would inform segregation analysis for at least a subset of
genes and carefully selected families. All laboratories that
offer any form of family studies reported that the program
began the same time they started offering clinical cancer gene
testing. When asked howmany families have been eligible for
family studies and what the reclassification Bsuccess^ rate
was, each laboratory reported nomechanism for keeping track
of how many patients were eligible, offered participation, or
ultimately how many variants were reclassified due to suc-
cessful co-segregation analysis via family studies. One inter-
viewee explained that although there were many different
ways and reasons a VUS could be reclassified, the reason







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1150 Garrett et al.
why it was being reclassified, such as family study informa-
tion, wasn’t being tracked.
In general, offering family studies was a common but not
necessarily uniform practice for these clinical laboratories that
perform genetic testing for hereditary cancer risk. Some of the
most significant differences between laboratories are in the
process for family studies. Some clinical laboratories work
with patients and genetic counselors encouraging individuals
to reach out to known family members and identify additional
relatives in order to reclassify variants. For most clinical lab-
oratories, however, family studies were only offered in select-
ed situations where VUS reclassification is most likely to be
possible or only for selected genes. Some laboratories offer
family segregation studies to any interested family on a fee-
for-service basis.
Motivation to Develop General Online Resources
for Family Based VUS Classification
As can be seen in Table 1, many clinical genetics laboratories
currently offer family studies programs. These programs are
diverse in how they operate and many place the onus on ge-
netics providers to order testing and to help patients identify
relatives and obtain biological specimens. Neither genetic
counseling time nor the laboratory resources used for family
study activities are reimbursed by insurance companies.
Limited genetics provider resources and laboratory opportu-
nities make it challenging for many willing patients to partic-
ipate in successful VUS reclassification efforts.
While advertising the availability of family testing services,
clinical laboratories simultaneously have mechanisms to con-
trol and restrict patient access to family segregation studies.
Commercial laboratories may feel obliged to offer family
based VUS reclassification services in limited instances be-
cause it is expected by genetics providers; however, there is
little incentive to assist patients in contacting the large number
of relatives necessary to reclassify VUS or to provide broad
access to education about family studies for VUS classifica-
tion as testing large numbers of relatives can be costly for
laboratories. More importantly, the time and effort needed to
work with patients and their relatives to build the 4–5 gener-
ation pedigrees that are usually necessary to classify VUS
would be administratively challenging and prohibitively
expensive.
A potential solution is to engage patients and their relatives
in expanding their own pedigree. Although there are limited
provider and laboratory resources for personally working with
and educating patients about pedigree building for family
studies, online genealogy resources and social networking
may facilitate patients identifying and contacting their rela-
tives themselves with minimal personal guidance. This obser-
vation sparked our interest in developing an educational
resource for patient-driven family history building for the pur-
pose of VUS classification.
FindMyVariant.org, a New Resource for VUS
Family Studies
We have developed a website that contains a patient-driven
VUS reclassification toolkit. The mains goals of the toolkit are
to: help individuals and families understand medical uncer-
tainty about rare variants; educate individuals and families
about ways to find more information about the variants that
are unique to their family; provide resources for individuals
who want to connect with their families to increase under-
standing about their genetic variants, and finally, provide re-
sources for individuals who want to connect with clinical lab-
oratories or research studies to learn more about their VUS.
The toolkit walks individuals step-by-step through the pro-
cess of gathering the family specific segregation information
required to reclassify any VUS that has been identified in
clinical testing. This toolkit explains the variant reclassifica-
tion process, teaches patients how to identify relatives who
may also carry the VUS, (i.e. informative relatives), and pro-
vides aids for contacting relatives and describing the need to
involve them in VUS classification. We sought insight from
clinical genetic counselors, molecular genetic pathologists,
bioethicists, and clinical geneticists to develop content for
the website, and we worked alongside an experienced web
developer to design the website in a patient- and user-
friendly manner.
The content of the website is designed and organized
around eight modules or Bsteps^ that a patient may encounter
when gathering family medical and variant data (Table 2). The
modules walk the patient through each step and include
graphics and examples. Screenshots of the home page and of
different modules are presented in Figs. 1, 2, 3 and 4. One
module lists several online genealogy and social networking
tools available to facilitate patients identifying and contacting
their relatives, and describes how these might be used in the
context of family history building for variant classification
(see Fig. 3). In addition to this content, the website contains
two examples that describe the experience of hypothetical
individuals going through the process of attempting to reclas-
sify the familial VUS following the tools offered in the
website (see Fig. 4).
BAmelia’s family^ is an example of a woman with breast
cancer who has a VUS in BRCA1. It includes descriptions of
Amelia talking to her family, trying to obtain tumor tissue
from a deceased ancestor, and using social media to find dis-
tant relatives. Ultimately, her VUS is tracking with cancer in
her family and can be reclassified as pathogenic, causing in-
creased cancer risk in relatives who carry the same variant.
Similarly, BCharlie’s family^ is an example of a man with




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1152 Garrett et al.
colon cancer and a VUS in APC that might be associated with
attenuated familial adenomatous polyposis. This example in-
cludes descriptions of a patient talking to his family,
uncovering information about his great-grandparents, and dis-
covering a branch of his family tree of which he was not
aware. The example concludes with Charlie learning that the
genetic variant he carries does not cause cancer risk and is
reclassified as likely benign. The goal of these examples is to
mimic as realistically as possible some of the smaller successes
and challenges a motivated patient could expect to come across
when attempting to gather all the information that is needed to
successfully classify a variant using co-segregation analysis in
their own family. Further, they demonstrate the two different
outcomes that can be expected upon successful completion of
family studies: in Amelia’s family, the VUS was reclassified to
pathogenic, while in Charlie’s family, his VUS was reclassified
as likely benign (See Fig. 4, Table 2).
One specific challenge to patients with VUS that are inter-
ested in family studies to learn more about their VUS, is the
difficulty in obtaining laboratory services to genotype and clas-
sify their variants. As illustrated in Table 1, each laboratory has
different processes and criteria for eligibility. Laboratories also
have different variant classification criteria and may draw dif-
ferent conclusions from the same family data (Yorczyk et al.
2015). Although, the BLaboratory Testing andAsking Relatives
About Participation in VUS Classification^ module of the web
tool lists clinical laboratories and research investigations in-
volved in family studies and provides links to relevant informa-
tion, we could not outline next steps for interacting with clinical
and research laboratories because there is no uniform process.
This is a stage in family studies for variant classification where
the patient will necessarily need to contact the testing laboratory
for guidance about how to proceed.
Discussion
The issue of large numbers of patients with variants of uncer-
tain significance is already a problem for medical genetics
practice (Culver et al. 2013; O’Neill et al. 2009; Lindor et al.
2013), and may become greater as large-scale sequencing en-
ters clinical care. It is estimated that each individual has hun-
dreds of rare, family-specific variants that might be classified
as VUS. Interpreting VUS in clinical genetics creates chal-
lenges for health care providers, and their patients. Despite
the potential of family studies for VUS reclassification, the
resources available and offered to patients are limited.
We surveyed 12 laboratories offering NGS panels for cancer
genes that perform family studies for genetic variant classifica-
tion and provide a summary of eligibility criteria and processes
where these details are defined by the testing laboratories
reviewed.While not designed to be a formal survey of laboratory

































































































































































































































































































































































































































































































































Family Studies for Classification of Variants 1153
genetic counselors and other health professionals as they help
patients found to carry a VUS to understand potential next steps
for resolving its clinical significance.
While family studies have the potential to yield powerful data
to reclassify variants, the time and effort required to build pedi-
grees adequately for variant classification limit this potential. We
developed an educational website containing a patient-friendly
toolkit to help aid patients in working with research and clinical
laboratories to reclassify their own VUS. The modules were
developed to walk patients step by step through the process
and address some of the realistic challenges that might come
up along the way. Recognizing that each patient and family has
it’s own complexity and challenges, we offered two examples of
patients (Fig. 4: Amelia and Charlie, see screenshot) from fami-
lies suspicious for hereditary breast and hereditary colorectal
cancers, respectively, as representative examples.
While the website was developed with the above benefits in
mind, we recognize that this is a first attempt at designing a
patient-friendly toolkit for variant reclassification and conse-
quently, has limitations. At this time, the toolkit is designed for
English speaking patients. Further, while we have attempted to
build resources suitable for most patient education levels, we
realize that some of the concepts and content may be beyond
the comprehension level of some patients or their relatives.
Because the website conveys complex terms in a simplified
level, it may be easier for patients of all educational levels to
use. Each patient’s family is different and subsequently, the num-
ber of individuals needed to reclassify aVUSwill be different for
each family, and based on the gene and rarity of the disease.
There are potential barriers to patients having access to the
Fig. 1 Screenshot of the home
page for FindMyVariant.org, a
public website. Patients can click
on the Bget started^ prompt and
will be introduced to a number of
different modules (designed in
order, as seen in Table 3) to walk
them through the process of
gathering family information to
help them classify their variant
Fig. 2 Screenshot with an example of an educational module found at
FindMyVariant.org. This module walks a patient through the basics of
using family information (i.e. via family studies) for family co-
segregation analysis, evidence standards for variant classification, and
classifying variant as either benign or pathogenic. It includes patient-
friendly information and examples
Fig. 3 Screenshot with an example of another educational module found
at FindMyVariant.org. This module walks a patient through the process of
using online genealogy and social networking tools and resources to find
and connect with relatives
1154 Garrett et al.
website, either because their ordering health care provider is not
aware that it exists, or they or their relatives may not have inter-
net or computer resources necessary to access the website.
Privacy and data security concerns prevented us from including
interactive pedigree building at this time; we are investigating
this as a possibility in future versions.
As more patients use the website, other challenges that we
did not anticipate are likely to be identified. Although reclas-
sification is theoretically possible for almost all families given
enough effort in pedigree building, practicalities may prevent
many individuals from being able to use family studies to
reclassify their variants such as individuals whowere adopted,
families who used assisted reproductive technologies utilizing
donor gametes, or individuals who have limited knowledge or
contact with relatives. Further, it is possible that only highly
motivated patients will be willing to make the effort to grow
their family histories to the point where they are able to clas-
sify their variants. Each laboratory we interviewed uses dif-
ferent rubrics for identifying individuals that qualify for fam-
ily studies and for reclassifying VUS through family studies.
Laboratories will undoubtedly respond differently to patient
efforts to grow their pedigrees for successful co-segregation
analysis. There are still many unanswered questions about
VUS classification. Few laboratories report keeping quality
records of the success rate of family studies, so future studies
will be needed to explore patient satisfaction with VUS clas-
sification activities and outcome metrics of these efforts.
Conclusion
In the current paradigm of multi-gene panel testing, the return
of a result with one or more VUS’s is a challenge faced by
genetic and other health care providers and ultimately, their
patients and families. Many laboratories are involved in
conducting family studies for variant reclassification with di-
verse protocols and eligibility criteria.
Engaged patients who are empowered to overcome this
barrier to VUS reclassification may make it possible for var-
iant reclassification to shift from that of a research activity, to a
clinical activity enabling individualized genomic medicine. In
addition to enhancing understanding of rare variants encoun-
tered in clinical testing, this approach could provide a signif-
icant benefit to families faced with VUS findings. We have
described a web tool that responds to this need, enabling pa-
tients to take charge of their genetic information in the age of
genomic medicine.
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